StockData
BridgeBio Oncology Therapeutics, Inc. logo

BridgeBio Oncology Therapeutics, Inc. (BBOT) stock

BBOTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$1.94−0.04 (-2.02%)

Close on Nov 17, 2026Market cap $155.54MP/E –Yield –

BridgeBio Oncology Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

BridgeBio Oncology Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$198.96M. For fiscal 2025 it was -$145.82M.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$145.82M–
FY2024Dec 31, 2024-$80.86M–
FY2023Dec 31, 2023-$41.69K–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$60.19M–
Q1 FY2026Mar 31, 2026-$46.18M–
Q4 FY2025Dec 31, 2025-$43.41M–
Q3 FY2025Sep 30, 2025-$49.18M–
Q2 FY2025Jun 30, 2025-$30.09M–
Q1 FY2025Mar 31, 2025-$23.14M–
Q4 FY2024Dec 31, 2024-$21.88M–
Q3 FY2024Sep 30, 2024-$19.66M–
Q2 FY2024Jun 30, 2024-$152.34K–
Q1 FY2024Mar 31, 2024-$66.70K–

More BridgeBio Oncology Therapeutics figures

See a number that looks wrong?